Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.12
BDX's Cash to Debt is ranked lower than
88% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.21 vs. BDX: 0.12 )
Ranked among companies with meaningful Cash to Debt only.
BDX' s 10-Year Cash to Debt Range
Min: 0.04  Med: 0.52 Max: 1.03
Current: 0.12
0.04
1.03
Equity to Asset 0.27
BDX's Equity to Asset is ranked lower than
87% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. BDX: 0.27 )
Ranked among companies with meaningful Equity to Asset only.
BDX' s 10-Year Equity to Asset Range
Min: 0.25  Med: 0.48 Max: 0.63
Current: 0.27
0.25
0.63
Interest Coverage 11.90
BDX's Interest Coverage is ranked lower than
68% of the 111 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.79 vs. BDX: 11.90 )
Ranked among companies with meaningful Interest Coverage only.
BDX' s 10-Year Interest Coverage Range
Min: 7.22  Med: 14.59 Max: 42.29
Current: 11.9
7.22
42.29
F-Score: 4
Z-Score: 2.12
M-Score: -1.61
WACC vs ROIC
10.19%
9.68%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 12.53
BDX's Operating margin (%) is ranked higher than
67% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.48 vs. BDX: 12.53 )
Ranked among companies with meaningful Operating margin (%) only.
BDX' s 10-Year Operating margin (%) Range
Min: 14.62  Med: 17.13 Max: 23.05
Current: 12.53
14.62
23.05
Net-margin (%) 8.65
BDX's Net-margin (%) is ranked higher than
66% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.54 vs. BDX: 8.65 )
Ranked among companies with meaningful Net-margin (%) only.
BDX' s 10-Year Net-margin (%) Range
Min: 7.59  Med: 12.69 Max: 17.87
Current: 8.65
7.59
17.87
ROE (%) 13.62
BDX's ROE (%) is ranked higher than
76% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.29 vs. BDX: 13.62 )
Ranked among companies with meaningful ROE (%) only.
BDX' s 10-Year ROE (%) Range
Min: 15.56  Med: 21.71 Max: 28.17
Current: 13.62
15.56
28.17
ROA (%) 4.13
BDX's ROA (%) is ranked higher than
58% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.43 vs. BDX: 4.13 )
Ranked among companies with meaningful ROA (%) only.
BDX' s 10-Year ROA (%) Range
Min: 6.66  Med: 10.31 Max: 14.79
Current: 4.13
6.66
14.79
ROC (Joel Greenblatt) (%) 22.57
BDX's ROC (Joel Greenblatt) (%) is ranked higher than
68% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.56 vs. BDX: 22.57 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BDX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 20.06  Med: 33.48 Max: 46.69
Current: 22.57
20.06
46.69
Revenue Growth (3Y)(%) 7.30
BDX's Revenue Growth (3Y)(%) is ranked higher than
63% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. BDX: 7.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BDX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 4.4  Med: 8.30 Max: 11.9
Current: 7.3
4.4
11.9
EBITDA Growth (3Y)(%) 3.30
BDX's EBITDA Growth (3Y)(%) is ranked lower than
60% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.70 vs. BDX: 3.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BDX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0.2  Med: 9.00 Max: 15.7
Current: 3.3
0.2
15.7
EPS Growth (3Y)(%) 4.10
BDX's EPS Growth (3Y)(%) is ranked lower than
52% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. BDX: 4.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BDX' s 10-Year EPS Growth (3Y)(%) Range
Min: -0.6  Med: 11.40 Max: 21.9
Current: 4.1
-0.6
21.9
» BDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

BDX Guru Trades in Q3 2014

Ray Dalio 25,358 sh (New)
Paul Tudor Jones 13,358 sh (+95.24%)
First Eagle Investment 829,770 sh (+42.41%)
Jim Simons 2,198,100 sh (+41.75%)
Joel Greenblatt 101,597 sh (+26.52%)
Richard Pzena 2,731,408 sh (+5.04%)
Robert Olstein 54,000 sh (unchged)
Vanguard Health Care Fund 2,393,100 sh (unchged)
Michael Price 135,000 sh (unchged)
Yacktman Focused Fund 450,000 sh (unchged)
Yacktman Fund 660,000 sh (unchged)
Pioneer Investments 1,007,206 sh (unchged)
Ruane Cunniff Sold Out
Donald Yacktman 1,303,596 sh (-0.05%)
Jeff Auxier 39,900 sh (-0.13%)
Bill Frels 5,053 sh (-0.69%)
Dodge & Cox 16,510 sh (-1.61%)
Jeremy Grantham 1,363,503 sh (-4.76%)
Mario Gabelli 501,272 sh (-8.00%)
Manning & Napier Advisors, Inc 1,771,592 sh (-26.20%)
John Hussman 50,000 sh (-71.43%)
» More
Q4 2014

BDX Guru Trades in Q4 2014

Steven Cohen 528,800 sh (New)
Jim Simons 2,648,700 sh (+20.50%)
Vanguard Health Care Fund 2,635,600 sh (+10.13%)
John Hussman 50,000 sh (unchged)
Bill Frels 5,053 sh (unchged)
Joel Greenblatt Sold Out
Donald Yacktman Sold Out
Manning & Napier Advisors, Inc Sold Out
Yacktman Focused Fund Sold Out
Yacktman Fund Sold Out
Dodge & Cox 15,730 sh (-4.72%)
Pioneer Investments 956,515 sh (-5.03%)
Jeff Auxier 37,875 sh (-5.08%)
Jeremy Grantham 1,280,701 sh (-6.07%)
Robert Olstein 48,000 sh (-11.11%)
Mario Gabelli 423,359 sh (-15.54%)
First Eagle Investment 668,683 sh (-19.41%)
Paul Tudor Jones 6,919 sh (-48.20%)
Ray Dalio 9,758 sh (-61.52%)
Michael Price 40,000 sh (-70.37%)
Richard Pzena 402,735 sh (-85.26%)
» More
Q1 2015

BDX Guru Trades in Q1 2015

Ken Fisher 1,399 sh (New)
Caxton Associates 20,000 sh (New)
Joel Greenblatt 19,341 sh (New)
Paul Tudor Jones 9,790 sh (+41.49%)
Vanguard Health Care Fund 3,075,487 sh (+16.69%)
Pioneer Investments 965,061 sh (+0.89%)
John Hussman 50,000 sh (unchged)
Michael Price Sold Out
Ray Dalio Sold Out
Bill Frels 5,005 sh (-0.95%)
First Eagle Investment 659,598 sh (-1.36%)
Jeremy Grantham 1,253,214 sh (-2.15%)
Dodge & Cox 15,330 sh (-2.54%)
Richard Pzena 373,824 sh (-7.18%)
Mario Gabelli 387,147 sh (-8.55%)
Robert Olstein 41,000 sh (-14.58%)
Jim Simons 1,953,666 sh (-26.24%)
Steven Cohen 312,800 sh (-40.85%)
Jeff Auxier 13,625 sh (-64.03%)
» More
Q2 2015

BDX Guru Trades in Q2 2015

Ray Dalio 15,358 sh (New)
Jeff Auxier 30,175 sh (+121.47%)
First Eagle Investment 1,308,855 sh (+98.43%)
Robert Olstein 49,000 sh (+19.51%)
Ken Fisher 1,656 sh (+18.37%)
Steven Cohen 346,200 sh (+10.68%)
Bill Frels 5,217 sh (+4.24%)
Richard Pzena 373,824 sh (unchged)
John Hussman 50,000 sh (unchged)
Vanguard Health Care Fund 3,075,487 sh (unchged)
Caxton Associates Sold Out
Dodge & Cox 15,238 sh (-0.60%)
Pioneer Investments 937,719 sh (-2.83%)
Jim Simons 1,829,366 sh (-6.36%)
Joel Greenblatt 17,750 sh (-8.23%)
Jeremy Grantham 1,097,314 sh (-12.44%)
Mario Gabelli 325,013 sh (-16.05%)
Paul Tudor Jones 4,800 sh (-50.97%)
» More
» Details

Insider Trades

Latest Guru Trades with BDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 33.39
BDX's P/E(ttm) is ranked lower than
63% of the 113 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.00 vs. BDX: 33.39 )
Ranked among companies with meaningful P/E(ttm) only.
BDX' s 10-Year P/E(ttm) Range
Min: 10.23  Med: 19.02 Max: 37.16
Current: 33.39
10.23
37.16
Forward P/E 16.03
BDX's Forward P/E is ranked higher than
72% of the 75 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.74 vs. BDX: 16.03 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 34.90
BDX's PE(NRI) is ranked lower than
67% of the 112 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.40 vs. BDX: 34.90 )
Ranked among companies with meaningful PE(NRI) only.
BDX' s 10-Year PE(NRI) Range
Min: 13.02  Med: 19.41 Max: 37.2
Current: 34.9
13.02
37.2
P/B 3.97
BDX's P/B is ranked lower than
63% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.91 vs. BDX: 3.97 )
Ranked among companies with meaningful P/B only.
BDX' s 10-Year P/B Range
Min: 2.96  Med: 4.08 Max: 5.59
Current: 3.97
2.96
5.59
P/S 2.93
BDX's P/S is ranked lower than
55% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. BDX: 2.93 )
Ranked among companies with meaningful P/S only.
BDX' s 10-Year P/S Range
Min: 1.95  Med: 2.68 Max: 3.54
Current: 2.93
1.95
3.54
PFCF 30.91
BDX's PFCF is ranked lower than
57% of the 83 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.56 vs. BDX: 30.91 )
Ranked among companies with meaningful PFCF only.
BDX' s 10-Year PFCF Range
Min: 12.84  Med: 17.97 Max: 35.08
Current: 30.91
12.84
35.08
POCF 17.49
BDX's POCF is ranked higher than
53% of the 114 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.43 vs. BDX: 17.49 )
Ranked among companies with meaningful POCF only.
BDX' s 10-Year POCF Range
Min: 8.76  Med: 11.99 Max: 19.46
Current: 17.49
8.76
19.46
EV-to-EBIT 32.66
BDX's EV-to-EBIT is ranked lower than
75% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.58 vs. BDX: 32.66 )
Ranked among companies with meaningful EV-to-EBIT only.
BDX' s 10-Year EV-to-EBIT Range
Min: 9.2  Med: 14.10 Max: 37.5
Current: 32.66
9.2
37.5
PEG 9.18
BDX's PEG is ranked lower than
91% of the 66 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.66 vs. BDX: 9.18 )
Ranked among companies with meaningful PEG only.
BDX' s 10-Year PEG Range
Min: 0.92  Med: 1.73 Max: 23.54
Current: 9.18
0.92
23.54
Shiller P/E 23.64
BDX's Shiller P/E is ranked higher than
60% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.14 vs. BDX: 23.64 )
Ranked among companies with meaningful Shiller P/E only.
BDX' s 10-Year Shiller P/E Range
Min: 13.74  Med: 20.69 Max: 33.31
Current: 23.64
13.74
33.31
Current Ratio 1.40
BDX's Current Ratio is ranked lower than
78% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.41 vs. BDX: 1.40 )
Ranked among companies with meaningful Current Ratio only.
BDX' s 10-Year Current Ratio Range
Min: 1.17  Med: 2.12 Max: 5.82
Current: 1.4
1.17
5.82
Quick Ratio 0.95
BDX's Quick Ratio is ranked lower than
77% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.60 vs. BDX: 0.95 )
Ranked among companies with meaningful Quick Ratio only.
BDX' s 10-Year Quick Ratio Range
Min: 0.7  Med: 1.47 Max: 5.1
Current: 0.95
0.7
5.1
Days Inventory 128.22
BDX's Days Inventory is ranked higher than
51% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 128.59 vs. BDX: 128.22 )
Ranked among companies with meaningful Days Inventory only.
BDX' s 10-Year Days Inventory Range
Min: 103.84  Med: 120.47 Max: 154.55
Current: 128.22
103.84
154.55
Days Sales Outstanding 63.71
BDX's Days Sales Outstanding is ranked lower than
52% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.01 vs. BDX: 63.71 )
Ranked among companies with meaningful Days Sales Outstanding only.
BDX' s 10-Year Days Sales Outstanding Range
Min: 51.3  Med: 60.94 Max: 86.75
Current: 63.71
51.3
86.75

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.72
BDX's Dividend Yield is ranked higher than
64% of the 149 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.45 vs. BDX: 1.72 )
Ranked among companies with meaningful Dividend Yield only.
BDX' s 10-Year Dividend Yield Range
Min: 1.05  Med: 1.77 Max: 2.44
Current: 1.72
1.05
2.44
Dividend Payout 0.58
BDX's Dividend Payout is ranked higher than
80% of the 86 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.34 vs. BDX: 0.58 )
Ranked among companies with meaningful Dividend Payout only.
BDX' s 10-Year Dividend Payout Range
Min: 0.16  Med: 0.27 Max: 2.07
Current: 0.58
0.16
2.07
Dividend growth (3y) 10.00
BDX's Dividend growth (3y) is ranked higher than
52% of the 54 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.20 vs. BDX: 10.00 )
Ranked among companies with meaningful Dividend growth (3y) only.
BDX' s 10-Year Dividend growth (3y) Range
Min: 2.6  Med: 12.90 Max: 29.1
Current: 10
2.6
29.1
Yield on cost (5-Year) 2.82
BDX's Yield on cost (5-Year) is ranked higher than
67% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.61 vs. BDX: 2.82 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
BDX' s 10-Year Yield on cost (5-Year) Range
Min: 1.72  Med: 2.90 Max: 4
Current: 2.82
1.72
4
Share Buyback Rate 4.40
BDX's Share Buyback Rate is ranked higher than
95% of the 132 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.30 vs. BDX: 4.40 )
Ranked among companies with meaningful Share Buyback Rate only.
BDX' s 10-Year Share Buyback Rate Range
Min: 6  Med: 1.00 Max: -1.1
Current: 4.4

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.65
BDX's Price/Projected FCF is ranked higher than
52% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.76 vs. BDX: 1.65 )
Ranked among companies with meaningful Price/Projected FCF only.
BDX' s 10-Year Price/Projected FCF Range
Min: 0.96  Med: 1.45 Max: 3.81
Current: 1.65
0.96
3.81
Price/DCF (Earnings Based) 2.48
BDX's Price/DCF (Earnings Based) is ranked lower than
68% of the 19 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.72 vs. BDX: 2.48 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.10
BDX's Price/Median PS Value is ranked higher than
50% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. BDX: 1.10 )
Ranked among companies with meaningful Price/Median PS Value only.
BDX' s 10-Year Price/Median PS Value Range
Min: 0.6  Med: 0.94 Max: 1.32
Current: 1.1
0.6
1.32
Earnings Yield (Greenblatt) (%) 3.11
BDX's Earnings Yield (Greenblatt) (%) is ranked higher than
51% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. BDX: 3.11 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BDX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 2.7  Med: 7.10 Max: 10.8
Current: 3.11
2.7
10.8
Forward Rate of Return (Yacktman) (%) 5.28
BDX's Forward Rate of Return (Yacktman) (%) is ranked lower than
67% of the 92 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 12.13 vs. BDX: 5.28 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BDX' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 5.1  Med: 16.15 Max: 19.7
Current: 5.28
5.1
19.7

Analyst Estimate

Sep15 Sep16 Sep17
Revenue(Mil) 10,401 12,814 13,254
EPS($) 7.04 8.41 9.35
EPS without NRI($) 7.04 8.41 9.35

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:BOX.Germany, BDX.Switzerland, 0R19.UK,
Becton Dickinson & Co was incorporated under the laws of the State of New Jersey in November 1906. The Company is a medical technology company engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, general public and the pharmaceutical industry. Its operations include three business segments; BD Medical, BD Diagnostics and BD Biosciences. BD Medical produces an array of medical devices that are used in a range of healthcare settings. It includes the safety-engineered injection, infusion and surgery products. BD Medical's product lines include needles, syringes and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for the self-injection of insulin and other drugs used in the treatment of diabetes; prefill able drug delivery devices provided to pharmaceutical companies and sold to end-users as drug/device combinations; surgical blades/scalpels and regional anesthesia needles and trays; critical care monitoring devices; ophthalmic surgical instruments; and sharps disposal containers. BD Diagnostics provide products for the safe collection and transport of diagnostic specimens, as well as instrument systems and reagents to detect a range of infectious diseases, healthcare-associated infections (HAIs) and cancers. BD Diagnostics' products include integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing systems; molecular testing systems for sexually transmitted diseases and HAIs; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; and plated media. BD Biosciences produces research and clinical tools that facilitate the study of cells, and the components of cells, to understand disease processes. BD Biosciences' product lines include fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life sciences research; cell imaging systems; laboratory products for tissue culture and fluid handling; diagnostic assays; and cell culture media supplements for biopharmaceutical manufacturing. The customers served by BD Biosciences are research and clinical laboratories; academic and government institutions; pharmaceutical and biotechnology companies; hospitals; and blood banks. The products sold by BD outside the United States are needles and syringes; insulin syringes and pen needles; diagnostic systems; BD Vacutainer brand blood collection products; BD Hypak brand prefillable syringe systems; infusion therapy products; flow cytometry instruments and reagents; and disposable laboratory products. It has manufacturing operations outside the United States, Brazil, Canada, China, France, Germany, Hungary, India, Ireland, Japan, Mexico, t
» More Articles for BDX

Headlines

Articles On GuruFocus.com
Becton and Dickinson: A Long-Term Bet Jul 08 2015 
Bill Frels' Stocks With Highest-Growing Yields Jun 26 2015 
Bill Frels' Stocks With Growing Yields Jun 27 2015 
Medtronic Inc. (MDT) Dividend Stock Analysis Feb 25 2015 
Becton and Dickinson´s Expansion into Emerging Markets Feb 10 2015 
ok Jan 31 2015 
The World’s Top 10 Financial Bloggers Jan 12 2015 
Becton, Dickinson and Co. (BDX) Dividend Stock Analysis Nov 19 2014 
Dividend Aristocrats in Focus Part 18 of 54: Becton, Dickinson & Company Oct 14 2014 
Weekly 52-Week Highs Highlight: BDX, DUK, CFN, INFY Oct 12 2014 

More From Other Websites
The 10 Most Recession-Proof Dividend Aristocrats Aug 26 2015
Budimex completes works at Warsaw Chopin Airport Aug 26 2015
BD to Acquire Cellular Research to Develop a Leading Genomics Platform for Single Cell Analysis Aug 25 2015
BD to Acquire Cellular Research to Develop a Leading Genomics Platform for Single Cell Analysis Aug 25 2015
Becton Dickinson gets vote of confidence Aug 21 2015
Becton, Dickinson & Co. Earnings Q2*, 2015 Aug 18 2015
BECTON DICKINSON & CO Financials Aug 13 2015
Medical Device Makers Top Tamarack Capital’s Portfolio Aug 13 2015
Ongoing commissioning and finishing works in the incineration plant in Białystok Aug 13 2015
Suwałki are going to have a ring road Aug 13 2015
ICU Medical, Inc.: Leads amongst peers with strong fundamentals Aug 12 2015
Current report no 52 / 2015 Aug 10 2015
10-Q for Becton, Dickinson & Co. Aug 09 2015
Barron's Recap: Time To Buy Commodities Aug 09 2015
A Bigger Becton Dickinson Looks Like a Buy Aug 07 2015
Company News for August 07, 2015 - Corporate Summary Aug 07 2015
Edited Transcript of BDX earnings conference call or presentation 6-Aug-15 12:00pm GMT Aug 06 2015
Becton, Dickinson Tops Q3 Earnings, Lags Sales; View Up - Analyst Blog Aug 06 2015
Becton, Dickinson (BDX) Beat On Q3 Earnings; Revenues Lag - Tale of the Tape Aug 06 2015
Becton, Dickinson and Co Earnings Call scheduled for 8:00 am ET today Aug 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK